Inositol polyphosphate 5-phosphatase OCRL
From Proteopedia
(Difference between revisions)
(New page: ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='3qbt' size='340' side='right' caption='Caption for this structure' scene=''> This is a default text for you...) |
|||
Line 1: | Line 1: | ||
- | == | + | ==OCRL-1 mutations causing Lowe syndrome== |
<StructureSection load='3qbt' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='3qbt' size='340' side='right' caption='Caption for this structure' scene=''> | ||
- | This is a default text for your page '''Alois Zdrha/Sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
- | You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue. | ||
== Function == | == Function == | ||
== Disease == | == Disease == | ||
+ | Disease | ||
+ | Lowe syndrome, formally called oculocerebrorenal syndrome, oculocerebrorenal syndrome of Lowe or OCRL, is an X-linked multisystemic disorder mainly involving eyes, nervous system (both the central and the peripheral) and kidneys. However, defects in other systems are observed as well. The syndrome is quite rare, its prevalence is 1 in 500 000 in the general population (based on the observations of the American Lowe Syndrome Association and the Italian Association of Lowe syndrome). Almost all of the patients are male. The syndrome is believed to occur worldwide as there are documented cases in America, Europe, Australia, Japan and India.<ref name="Lowe syndrome">PMID: 20301653</ref><ref name="Oculocerebrorenal">PMID: 27011217</ref> | ||
- | == | + | There is quite a wide range of different phenotypes in Lowe syndrome patients so the individual cases may vary a lot. Amongst the hallmarks of Lowe syndrome are dense congenital cataracts, some degree of intellectual impairment and mental retardation (usually severe), severe growth retardation and generalized hypotonia, proximal renal tubular dysfunction of the renal Fanconi type, which is slowly progressing towards renal failure/end-stage renal disease (ERSD) in adulthood.<ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/> |
+ | |||
+ | Renal tubular dysfunction is accompanied by low-molecular-weight (LMW) proteinuria in all patients. Aminoaciduria, phosphaturia, hypercalciuria, polyuria, bicarbonate, sodium and potassium wasting, renal tubular acidosis are often present as well. All affected people have impaired vision even after cataracts are removed. Hypotonia may improve a little with age, but normal state is never achieved. Hypotonia is connected with joint hypermobility which can result in joint dislocation. Almost all patients suffer from osteopenia, some patients suffer from repeated bone fractures with poor healing and in about 50 % of patients, scoliosis is present. Other frequent physical complications of Lowe syndrome are arthritis, dental malformations, bleeding disorder (platelet malfunction) and cryptorchidism (undescended testes). In some cases cysts on the skin, in the mouth, kidneys and brain were found.<ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/> | ||
+ | |||
+ | Some kinds of seizures occur in up to 50 % of patients. Behavioral problems are usually present in Lowe syndrome patients. Those may include maladaptive behaviors, obsessive-compulsive behaviors, stubbornness, repetitive behavior (such as repetitive purposeless movements), tantrums and aggressive or self-abusive behavior.<ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/> | ||
+ | |||
+ | Some of the defects, such as congenital cataracts and hypotonia, are present at birth while others evolve later. The absence of deep tendon reflexes is often observed soon after birth as well which may point to hypotonia and together with cataracts it is the first diagnostic clue. LWM proteinuria is also detected soon after birth and it is the first symptom of tubular dysfunction that appears. LMW proteinuria is present in all patients. Usually, life span is not longer than 40 years. <ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/><ref name="Evidence">PMID: 8599350</ref> | ||
+ | |||
+ | As for heterozygous females, most of them have lens opacities in post-pubertal age. Besides that, manifestations of the Lowe syndrome are usually not observed.<ref name="Lowe syndrome"/> | ||
+ | |||
+ | == Diagnosis and treatment == | ||
+ | Lowe syndrome is inherited in an X-linked manner. About two-thirds of cases are transmitted by maternal carriers. Affected males are not known to reproduce. Female carriers show heterozygous female phenotype, which might indicate the need for genetic counseling. The remaining one third (approximately) is attributed to a de novo variant. There is a high risk (4,5%) of germline mosaicism in Lowe syndrome families. If OCRL pathogenic variant has been identified in a family member, prenatal genetic testing can be performed. Unfortunately, it can not say anything about the severity of the disease. <ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/><ref name="Evidence"/> | ||
+ | |||
+ | Treatment is only symptomatic. Patients usually require more than one medical specialist to manage various clinical problems.<ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/><ref name="Evidence"/ref> Regular surveillance by many specialists is also needed in many fields for the whole lifetime. <ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/> | ||
== Structural highlights == | == Structural highlights == |
Revision as of 21:41, 27 April 2021
OCRL-1 mutations causing Lowe syndrome
|
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Lewis RA, Nussbaum RL, Brewer ED. Lowe Syndrome PMID:20301653
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Bokenkamp A, Ludwig M. The oculocerebrorenal syndrome of Lowe: an update. Pediatr Nephrol. 2016 Dec;31(12):2201-2212. doi: 10.1007/s00467-016-3343-3. Epub , 2016 Mar 24. PMID:27011217 doi:http://dx.doi.org/10.1007/s00467-016-3343-3
- ↑ 3.0 3.1 Kenworthy L, Charnas L. Evidence for a discrete behavioral phenotype in the oculocerebrorenal syndrome of Lowe. Am J Med Genet. 1995 Nov 20;59(3):283-90. doi: 10.1002/ajmg.1320590304. PMID:8599350 doi:http://dx.doi.org/10.1002/ajmg.1320590304
- ↑ Regular surveillance by many specialists is also needed in many fields for the whole lifetime. <ref></ref><ref></ref>
Structural highlights
This is a sample scene created with SAT to by Group, and another to make of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.